Medicaid Services Investment and Accountability Act of 2019

Bill: 116-hr-1839
Sponsor: Rep. Ruiz, Raul [D-CA-36]
Introduced: 2019-03-21 in the House
Policy area: Health
Subjects: Birth defects
Blood and blood diseases
Business records
Cardiovascular and respiratory health
Child health
Civil actions and liability
Disability and paralysis
Emergency medical services and trauma care
Family services
HIV/AIDS
Health care costs and insurance
Health care coverage and access
Health care quality
Health personnel
Health programs administration and funding
Health promotion and preventive care
Health technology, devices, supplies
Hereditary and development disorders
Home and outpatient care
Hospital care
Inflation and prices
Long-term, rehabilitative, and terminal care
Marriage and family status
Medicaid
Medical education
Mental health
Musculoskeletal and skin diseases
Neurological disorders
Prescription drugs
Sex and reproductive health
State and local courts
State and local finance

Summary:
action_date: 2019-03-21
text: 

Medicaid Services Investment and Accountability Act of 2019

 
This bill alters several Medicaid programs and funding provisions.
 
For example, the bill temporarily extends the applicability of Medicaid eligibility criteria that protect against spousal impoverishment for recipients of home- and community-based services.
 
The bill also establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate.
 
Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).

action_date: 2019-04-18
text: 

Medicaid Services Investment and Accountability Act of 2019

 
This bill alters several Medicaid programs and funding provisions.
 
(Sec. 2) The bill temporarily extends the applicability of Medicaid eligibility criteria that protect against spousal impoverishment for recipients of home- and community-based services.
 
(Sec. 3) The bill also establishes a state Medicaid option to provide for medical assistance with respect to coordinated care provided through a health home (i.e., a designated provider or team of health-care professionals) for children with medically complex conditions. States must determine payment methodologies in accordance with specified requirements; payments also temporarily qualify for an enhanced federal matching rate.
 
(Sec. 4) The bill also temporarily extends the Medicaid demonstration program for certified community behavioral health clinics.
 
(Sec. 5) The bill increases funding available to the Money Follows the Person Rebalancing Demonstration Program. (Under this program, the Centers for Medicare & Medicaid Services may award grants to state Medicaid programs to assist states in increasing the use of home and community care for long-term care and decreasing the use of institutional care.) 
 
(Sec. 6) Further, drug manufacturers with Medicaid rebate agreements for covered outpatient drugs must disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).


Legislative actions:
action_date: 2019-04-18
text: Became Public Law No: 116-16.
action_date: 2019-04-18
text: Became Public Law No: 116-16.
action_date: 2019-04-18
text: Signed by President.
action_date: 2019-04-18
text: Signed by President.
action_date: 2019-04-10
text: Presented to President.
action_date: 2019-04-10
text: Presented to President.
action_date: 2019-04-10
text: Sponsor introductory remarks on measure. (CR H3224)
action_date: 2019-04-03
text: Message on Senate action sent to the House.
action_date: 2019-04-02
text: Passed Senate without amendment by Voice Vote. (consideration: CR S2203)
action_date: 2019-04-02
text: Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.(consideration: CR S2203)
action_date: 2019-03-26
text: Received in the Senate, read twice.
action_date: 2019-03-25
text: Motion to reconsider laid on the table Agreed to without objection.
action_date: 2019-03-25
text: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H2773-2776)
action_date: 2019-03-25
text: Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H2773-2776)
action_date: 2019-03-25
text: Considered as unfinished business. (consideration: CR H2781)
action_date: 2019-03-25
text: At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Burgess objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
action_date: 2019-03-25
text: DEBATE - The House proceeded with forty minutes of debate on H.R. 1839.
action_date: 2019-03-25
text: Considered under suspension of the rules. (consideration: CR H2773-2780)
action_date: 2019-03-25
text: Mr. Ruiz moved to suspend the rules and pass the bill, as amended.
action_date: 2019-03-22
text: Referred to the Subcommittee on Health.
action_date: 2019-03-21
text: Referred to the House Committee on Energy and Commerce.
action_date: 2019-03-21
text: Introduced in House
action_date: 2019-03-21
text: Introduced in House

Enacted as: number: 116-16